An Open-Label, 3-Part, 2-Period Study to Examine the Effect of Omeprazole (Part 1), Famotidine (Part 2), and of an Acidic Beverage (Part 3) on the Single-Dose Pharmacokinetics of Entinostat in Healthy Adult Subjects

Trial Profile

An Open-Label, 3-Part, 2-Period Study to Examine the Effect of Omeprazole (Part 1), Famotidine (Part 2), and of an Acidic Beverage (Part 3) on the Single-Dose Pharmacokinetics of Entinostat in Healthy Adult Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Entinostat (Primary) ; Famotidine (Primary) ; Omeprazole (Primary)
  • Indications Breast cancer; Hodgkin's disease; Leukaemia; Malignant melanoma; Non-small cell lung cancer; Renal cancer
  • Focus Pharmacokinetics
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 30 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 12 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top